Show simple item record

dc.contributor.authorRegueiro Lorenzo, Uxía
dc.contributor.authorLópez-López, M.
dc.contributor.authorVarela-Fernández, R.
dc.contributor.authorSobrino Moreiras, Tomas 
dc.contributor.authorDiez-Feijoo, E.
dc.contributor.authorLema Gesto, Isabel
dc.date.accessioned2025-08-26T11:22:59Z
dc.date.available2025-08-26T11:22:59Z
dc.date.issued2022
dc.identifier.citationRegueiro U, López-López M, Varela-Fernández R, Sobrino T, Diez-Feijoo E, Lema I. Immunomodulatory Effect of Human Lactoferrin on Toll-like Receptors 2 Expression as Therapeutic Approach for Keratoconus. International journal of molecular sciences. 2022;23(20).
dc.identifier.issn1422-0067
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/636708eb688cd71757e14553*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20926
dc.description.abstractKeratoconus (KC) is a corneal disorder whose etiology shares a close relationship with Lactoferrin (LTF) dysregulation and Toll-like Receptors 2 (TLR2) overexpression. This study shows how these two important biomarkers are clinically and molecularly interrelated, increasing knowledge about KC pathophysiology, and opening the door to future therapies. In this prospective clinical study, serum and tear LTF concentrations were quantified in 90 KC patients and 60 controls. A correlation analysis with multiple blood and tear immunoinflammatory mediators, and KC-associated tomographic parameters, was performed. An in vitro study using HEK-BlueTMhTLR2 cell cultures was also conducted to determine the expression and functionality of TLR2 under the influence of LTF treatment. As a result, a LTF decreased was observed in KC patients compared to controls (p < 0.0001), evidencing the strong correlation with TLR2 overexpression at systemic and ocular surface level, with inflammatory mediator upregulation and with KC severity. In stimulated cell cultures, TLR2 expression was decreased using 2 mg/mL of LTF. The levels of secreted embryonic alkaline phosphatase (SEAP) and interleukin-8 (IL-8) were also reduced in supernatants after LTF treatment. As conclusions, the dysregulation of LTF and TLR2 in the ocular surface of KC patients contributes to KC severity by maintaining a detrimental chronic immune-inflammatory state. The immunomodulatory properties of LTF on TLR2 expression suggest its potential as a therapeutic approach for KC.en
dc.description.sponsorshipThis project has been awarded grants from the Spanish Ministry of Economy and Competitiveness (I.L.: PI18/00159, Instituto de Salud Carlos III); Xunta de Galicia (Conselleria de Economia e Industria: IN607A2018/3 & T.S.: IN607D 2020/09), and the European Union program ERFD. T.S. (CPII17/00027) is recipient of a research contract from the Miguel Servet Program (National Institute of Health Carlos III). Similarly, U.R. recognizes the support from Xunta de Galicia (Galician Innovation Agency GAIN: IN606B-2021/001) postdoctoral fellowship, and M.L.L. recognizes the support from Spanish Research Network on Cerebrovascular Diseases INVICTUS PLUS (RD16/0019/0001) fellowship. R.V.F. acknowledge the financial support of the FIDIS (Health Research Institute of Santiago de Compostela Foundation). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleImmunomodulatory Effect of Human Lactoferrin on Toll-like Receptors 2 Expression as Therapeutic Approach for Keratoconus*
dc.typeArticleen
dc.authorsophosRegueiro, I. U.
dc.authorsophosLópez-López, M.
dc.authorsophosVarela-Fernández, R.
dc.authorsophosSobrino, T.
dc.authorsophosDiez-Feijoo, E.
dc.authorsophosLema
dc.identifier.doi10.3390/ijms232012350
dc.identifier.sophos636708eb688cd71757e14553
dc.issue.number20
dc.journal.titleInternational journal of molecular sciences*
dc.relation.projectIDSpanish Ministry of Economy and Competitiveness (Instituto de Salud Carlos III) [PI18/00159]; Xunta de Galicia (Conselleria de Economia e Industria) [IN607A2018/3, IN607D 2020/09]; European Union program ERFD; Miguel Servet Program (National Institute of Health Carlos III) [CPII17/00027]; Xunta de Galicia (Galician Innovation Agency) [GAIN: IN606B-2021/001]; Spanish Research Network on Cerebrovascular Diseases INVICTUS PLUS fellowship [RD16/0019/0001]; FIDIS (Health Research Institute of Santiago de Compostela Foundation)
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604127/pdf/ijms-23-12350.pdf;https://mdpi-res.com/d_attachment/ijms/ijms-23-12350/article_deploy/ijms-23-12350-v2.pdf?version=1666320535es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.subject.keywordINGOes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number23


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional